宋莉,颜红兵

• 1:阜外心血管病医院

摘要(Abstract)：

<正>药物洗脱支架(drug eluting stent,DES)通过在冠状动脉局部持续缓慢释放抗增殖药物来抑制新生内膜形成。与金属裸支架(bare metal stent,BMS)相比,DES再狭窄发生率由

关键词(KeyWords)：

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 宋莉,颜红兵

参考文献(References)：

• [1]吕树铮,宋现涛,陈韵岱.中国内地2006至2007年经皮冠状动脉介入治疗注册登记分析.中华心血管病杂志,2009,37:26-29.
• [2]Stone GW,Ellis SG,Cox DA,et al.A polymer-based,paclitaxeleluting stent in patients with coronary artery disease.NEngl J Med,2004,350:221-231.
• [3]MoRES JW,Leon MB,Popma JJ,et al.Sirolimus-eluting stentsversus standard stents in patients with stenosis in a nativecoronary artery.N Engl J Med,2003,349:1315-1323.
• [4]Corbett SJ,Cosgrave J,Melzi G,et al.Patterns of restenosisafter drug-eluting stent implantation:insights froma contemporaryand comparative analysis of sirolimus-and paclitaxel-elutingstents.Eur Heart J,2006,27:2330-2337.
• [5]Kitahara H,Kobayashi Y,Takebayashi H,et al.Angiographicpatterns of restenosis after sirolimus-eluting stent implantation.Circ J,2009,73:508-511.
• [6]Cosgrave J,Melzi G,Biondi-Zoccai GG,et al.Drug-eluting stentrestenosis:the pattern predicts the outcome.J Am Coll Cardiol,2006,47:2399-2404.
• [7]Morice MC,Colombo A,Meier B,et al.Sirolimus-vspaclitaxeleluting stents in de novo coronary artery lesions:theREALITY trial:a randomized controlled trial.JAMA,2006,295:895-904.
• [8]Windecker S,Serruys PW,Wandel S,et al.Biolimus-elutingstent with biodegradable polymer versus sirolimus-eluting stentwith durable polymer for coronary revascularisation(LEADERS):a randomized non-inferiority trial.Lancet,2008,372:1163-1173.
• [9]Zahn R,Hamm CW,Schneider S,et al.Incidence andpredictors of target vessel revascularization and clinical event ratesof the sirolimuseluting coronary stent(results fromthe prospectivemulticenter German Cypher Stent Registry).Am J Cardiol,2005,95:1302-1308.
• [10]Lemos PA,Serruys PW,van Domburg RT,et al.Unrestrictedutilization of sirolimus-eluting stents compared with conventionalbare stent implantation in the"real world":the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital(RESEARCH)registry.Circulation,2004,109:190-195.
• [11]Nayak AK,Kawamura A,Nesto RW,et al.Myocardial infarctionas a presentation of clinical in-stent restenosis.Circ J,2006,70:1026-1029.
• [12]Lee MS,Pessegueiro A,Zimmer R,et al.Clinical presentation ofpatients with in-stent restenosis in the drug-eluting stent era.JInvasive Cardiol,2008,20:401-403.
• [13]Bossi I,Klersy C,Black AJ,et al.In-stent restenosis:long-termoutcome and predictors of subsequent target lesionrevascularization after repeat balloon angioplasty.J Am CollCardiol,2000,35:1569-1576.
• [14]Chen MS,John JM,Chew DP,et al.Bare metal stent restenosisis not a benign clinical entity.Am Heart J,2006,151:1260-1264.
• [15]Yusuf RZ,Duan Z,Lamendola DE,et al.Paclitaxel resistance:molecular mechanisms and pharmacologic manipulation.CurrCancer Drug Targets,2003,3:1-19.
• [16]Huang S,Houghton PJ.Mechanisms of resistance to rapamycins.Drug Resist Updat,2001,4:378-391.
• [17]Cook S,Wenaweser P,Togni M,et al.Incomplete stentapposition and very late stent thrombosis after drug-eluting stentimplantation.Circulation,2007,115:2426-2434.
• [18]Hong MK,Mintz GS,Lee CW,et al.Late stent malappositionafter drug-eluting stent implantation:an intravascular ultrasoundanalysis with long-term follow-up.Circulation,2006,113:414-419.
• [19]Balakrishnan B,Tzafriri AR,Seifert P,et al.Strut position,blood flow,and drug deposition:implications for single andoverlapping drug-eluting stents.Circulation,2005,111:2958-2965.
• [20]Hwang CW,Levin AD,Jonas M,et al.Thrombosis modulatesarterial drug distribution for drug-eluting stents.Circulation,2005,111:1619-1626.
• [21]Hong MK,Mintz GS,Lee CW,et al.Intravascular ultrasoundpredictors of angiographic restenosis after sirolimus-eluting stentimplantation.Eur Heart J,2006,27:1305-1310.
• [22]Fujii K,Mintz GS,Kobayashi Y,et al.Contribution of stentunderexpansion to recurrence after sirolimus-eluting stentimplantation for in-stent restenosis.Circulation,2004,109:1085-1088.
• [23]Doi H,Maehara A,Mintz GS,et al.Classification and potentialmechanisms of intravascular ultrasound patterns of stent fracture.Am J Cardiol,2009,103:818-823.
• [24]Aoki J,Nakazawa G,Tanabe K,et al.Incidence and clinicalimpact of coronary stent fracture after sirolimus-eluting stentimplantation.Catheter Cardiovasc Interv,2007,69:380-386.
• [25]Lee MS,Jurewitz D,Aragon J,et al.Stent fracture associatedwith drug-eluting stents:clinical characteristics and implications.Catheter Cardiovasc Interv,2007,69:387-394.
• [26]Umeda H,Gochi T,Iwase M,et al.Frequency,predictors andoutcome of stent fracture after sirolimus-eluting stentimplantation.Int J Cardiol,2009,133:321-326.
• [27]Kereiakes DJ,Wang H,Popma JJ,et al.Periprocedural and lateconsequences of overlapping Cypher sirolimus-eluting stents:pooled analysis of five clinical trials.J Am Coll Cardiol,2006,48:21-31.
• [28]Costa MA,Angiolillo DJ,Tannenbaum M,et al.Impact of stentdeployment procedural factors on long-term effectiveness andsafety of sirolimus-eluting stents(final results of the multicenterprospective STLLR trial).Am J Cardiol,2008,101:1704-1711.
• [29]Alfonso F,P rez-Vizcayno MJ,Hernandez R,et al.Arandomized comparison of sirolimus-eluting stent with balloonangioplasty in patients with in-stent restenosis:results of theRestenosis Intrastent:Balloon Angioplasty Versus ElectiveSirolimus-Eluting Stenting(RIBS-II)trial.J Am Coll Cardiol,2006,47:2152-2160.
• [30]Holmes DR Jr,Teirstein P,Satler L,et al.Sirolimus-elutingstents vs vascular brachytherapy for in-stent restenosis withinbare-metal stents:the SISR randomized trial.JAMA,2006,295:1264-1273.
• [31]Stone GW,Ellis SG,O′Shaughnessy CD,et al.Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosiswithin baremetal stents:the TAXUS V ISR randomized trial.JAMA,2006,295:1253-1263.
• [32]Kim YH,Lee BK,Park DW,et al.Comparison withconventional therapies of repeated sirolimus-eluting stentimplantation for the treatment of drug-eluting coronary stentrestenosis.Am J Cardiol,2006,98:1451-1454.
• [33]Mishkel GJ,Moore AL,Markwell S,et al.Long-term outcomesafter management of restenosis or thrombosis of drug-elutingstents.J Am Coll Cardiol,2007,49:181-184.
• [34]Tagliareni F,La Manna A,Saia F,et al.Long-term clinicalfollow-up of drug-eluting stent restenosis treatment:retrospectiveanalysis from two high volume catheterization laboratories.EuroIntervention,2010,5:703-708.
• [35]Mehilli J,Byrne RA,Tiroch K,et al.Randomized trial ofpaclitaxelversus sirolimus-eluting stents for treatment of coronaryrestenosis in sirolimus-eluting stents:the ISAR-DESIRE 2(Intracoronary Stenting and Angiographic Results:Drug ElutingStents for In-Stent Restenosis 2)study.J Am Coll Cardiol,2010,55:2710-2716.
• [36]Scheller B,Hehrlein C,Bocksch W,et al.Treatment of coronaryin-stent restenosis with a paclitaxel-coated balloon catheter.NEngl J Med,2006,355:2113-2124.
• [37]Unverdorben M,Vallbracht C,Cremers B,et al.Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for thetreatment of coronary in-stent restenosis.Circulation,2009,119:2986-2994.